Brief Summary
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Intervention / Treatment
- Drug: AZD9829
- Drug: AZD9829
Inclusion Criteria:
- ≥18 years of age;
- CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;
- R/R AML;
- R/R HR-MDS with ≥5% bone marrowsoft, spongy tissue found in bones that makes blood cells blast at time of inclusion;
- Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
- ECOG performance status of ≤ 2.
The above is a summary, other inclusion criteria details may apply.